Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, 305 East Zhongshan Road, 210002 Nanjing, China.
Med Oncol. 2011 Mar;28(1):315-21. doi: 10.1007/s12032-010-9443-1. Epub 2010 Feb 9.
The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Relevant studies were identified by searching the Medline, Embase, CNKI and American Society of Clinical Oncology abstract databases. Inclusion criteria were patients with advanced NSCLC, received platinum-based chemotherapy, evaluation of polymorphism of ERCC1 and XPD and overall response rate (ORR). A total of 12 studies were included in this meta-analysis. For studies evaluating ERCC1 polymorphism at codon 118, the ORR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotype was 2.17 (95% confidence interval (CI), 1.43-3.33; P = 0.000). For studies evaluating XPD Asp312Asn and XPD Lys751Gln, the pooled OR was 1.33 (95% CI, 0.92-1.91; P = 0.13) and 1.02 (95% CI, 0.72-1.45; P = 0.915), respectively. The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T. However, XPD Asp312Asn and XPD Lys751Gln were not predictive makers for platinum-based chemotherapy in patients with advanced NSCLC.
发表的数据表明，接受铂类化疗的晚期非小细胞肺癌患者中 ERCC1 和 XPD 多态性的预测价值尚无定论。为了更准确地评估这种关系，进行了一项荟萃分析。通过搜索 Medline、Embase、CNKI 和美国临床肿瘤学会摘要数据库，确定了相关研究。纳入标准为：晚期 NSCLC 患者，接受铂类化疗，评估 ERCC1 和 XPD 多态性和总缓解率（ORR）。共有 12 项研究纳入了这项荟萃分析。对于评估 ERCC1 密码子 118 多态性的研究，野生型 C/C 基因型与杂合型 C/T 和 T/T 基因型的 ORR 为 2.17（95%置信区间[CI]，1.43-3.33；P=0.000）。对于评估 XPD Asp312Asn 和 XPD Lys751Gln 的研究，合并 OR 分别为 1.33（95%CI，0.92-1.91；P=0.13）和 1.02（95%CI，0.72-1.45；P=0.915）。结果表明，铂类化疗敏感性与 ERCC1 C118T 多态性显著相关。然而，XPD Asp312Asn 和 XPD Lys751Gln 不是晚期 NSCLC 患者铂类化疗的预测标志物。
